###begin article-title 0
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor-Dependent Control of Glucose Homeostasis
###end article-title 0
###begin p 1
###xml 36 56 36 56 <email xmlns:xlink="http://www.w3.org/1999/xlink">koneil@cntus.jnj.com</email>
Corresponding author: Karyn O'Neil, koneil@cntus.jnj.com
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-We have developed a novel platform for display and delivery of bioactive peptides that links the biological properties of the peptide to the pharmacokinetic properties of an antibody. Peptides engineered in the MIMETIBODY platform have improved biochemical and biophysical properties that are quite distinct from those of Fc-fusion proteins. CNTO736 is a glucagon-like peptide 1 (GLP-1) receptor agonist engineered in our MIMETIBODY platform. It retains many activities of native GLP-1 yet has a significantly enhanced pharmacokinetic profile. Our goal was to develop a long-acting GLP-1 receptor agonist with sustained efficacy.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
RESEARCH DESIGN AND METHODS-In vitro and in vivo activity of CNTO736 was evaluated using a variety of rodent cell lines and diabetic animal models.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 375 378 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
RESULTS-Acute pharmacodynamic studies in diabetic rodents demonstrate that CNTO736 reduces fasting and postprandial glucose, decreases gastric emptying, and inhibits food intake in a GLP-1 receptor-specific manner. Reduction of food intake following CNTO736 dosing is coincident with detection of the molecule in the circumventricular organs of the brain and activation of c-fos in regions protected by the blood-brain barrier. Diabetic rodents dosed chronically with CNTO736 have lower fasting and postprandial glucose and reduced body weight.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Taken together, our data demonstrate that CNTO736 produces a spectrum of GLP-1 receptor-dependent actions while exhibiting significantly improved pharmacokinetics relative to the native GLP-1 peptide.
###end p 6
###begin p 7
Published ahead of print at  on 21 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 461 462 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
Drug development strategies for therapeutic peptides continue to be challenging despite advances in technologies such as pegylation and lipidation (1-4). Although important biological processes are regulated by peptides, successful development of peptide drugs has been limited and transformation of a metabolically labile peptide into a drug remains challenging. In contrast, considerable advances have been made in the development of antibody therapeutics (5,6). A technology that could link the activity of a target peptide with the pharmacokinetic characteristics of an antibody would be a valuable addition to tools available for drug discovery. To address this need, we developed the MIMETIBODY platform as a novel technology for the display and delivery of bioactive peptides. Using protein design tools, we linked an antibody Fc domain to a bioactive glucagon-like peptide 1 (GLP-1) analog and engineered the construct for optimal biochemical and biophysical properties.
###end p 9
###begin p 10
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 621 623 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 624 626 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 704 706 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 707 709 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 851 853 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 854 856 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 690 695 <span type="species:ncbi:9606">human</span>
GLP-1 is a 30-amino acid peptide secreted from L-cells of the intestine following nutrient ingestion (7-10). GLP-1 is rapidly degraded in vivo with a half-life of <2 min and cleared via the kidney (11,12). When circulating glucose concentrations are elevated, GLP-1 increases insulin and decreases glucagon secretion from the pancreas and slows gastric emptying, thereby reducing glucose appearance in the circulation and enhancing glucose clearance from the circulation (13-15). In rodent models, GLP-1 expands beta-cell mass via induction of beta-cell proliferation and neogenesis and reduction of beta-cell apoptosis (16-20). The cytoprotective actions of GLP-1 also promote survival of human islets (21,22). Furthermore, GLP-1 reduces food intake, and therapy with GLP-1 receptor agonists has been associated with weight loss in clinical studies (23,24). Thus, GLP-1 receptor agonists are attractive therapeutic candidates for the treatment of type 2 diabetes.
###end p 10
###begin p 11
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 1015 1018 1015 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1126 1130 <span type="species:ncbi:10090">mice</span>
###xml 1135 1139 <span type="species:ncbi:10116">rats</span>
CNTO736 is a GLP-1 receptor agonist engineered in our MIMETIBODY platform that incorporates a GLP-1 peptide analogue genetically fused to a domain that includes the Fc portion of an antibody (25,26). In addition to an amino acid substitution in the peptide rendering it resistant to dipeptidyl peptidase IV (27,28), the increased molecular weight and pharmacokinetic properties of an Fc were expected to enable sustained delivery of a GLP-1 receptor agonist. We demonstrate that CNTO736 dose-dependently increases cAMP and insulin secretion from islets in a glucose-dependent manner. In rodent models of type 2 diabetes, acute dosing with CNTO736 lowers fasting and postprandial blood glucose with a significantly longer duration of action than native GLP-1, and chronic dosing with CNTO736 decreases body weight. Although CNTO736 is a large molecule that is not likely to efficiently cross the blood-brain barrier, it can be detected in the circumventricular organs of the brain following peripheral dosing, and c-fos expression is detected in regions that are protected by the blood-brain barrier. Food intake is reduced in mice and rats following peripheral dosing with CNTO736, correlating with the appearance of the molecule in the hypothalamus. Hence, the generation of stable bioactive peptide therapeutics with optimized pharmacokinetic properties may provide a new option for the treatment of metabolic disorders.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin title 13
Animal studies.
###end title 13
###begin p 14
###xml 79 127 79 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Guide for the Care and Use of Laboratory Animals</italic>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
All animal studies were performed according to the National Research Council's Guide for the Care and Use of Laboratory Animals and were approved by the internal institutional animal care and use committee. db/db mice were purchased from The Jackson Laboratories. For diet-induced obesity (DIO) mice experiments, C57BL/6J mice were maintained on a diet containing 60.9% kcal from fat from 4 weeks of age, and all animals achieved 3 consecutive weeks of diabetic fasting blood glucose (FBG) values (>120 mg/dl).
###end p 14
###begin title 15
Expression and purification of CNTO736.
###end title 15
###begin p 16
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 606 607 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 545 551 <span type="species:ncbi:9913">bovine</span>
CNTO736 was constructed by fusing a GLP-1 peptide analogue to a flexible Gly/Ser linker and a fragment of a V region heavy chain (VH) domain linked directly to the CH2 and CH3 domains of an Fc. The amino acid sequence is shown in Fig. 1A. Genes encoding CNTO736 or CNTO1996, a negative control molecule that lacks a GLP-1 segment, were cloned into a vector for mammalian expression under control of the cytomegalovirus promoter. For transient expression, HEK 293E cells were expanded (Dulbecco's modified Eagle's medium [Invitrogen] + 10% fetal bovine serum) and used to seed a 10-tier cell factory (5 x 107 cells in growth medium [1,200 ml]). Twenty-four hours later, the cells were transfected. The transfection mix was replaced with 293-SFMII medium (Invitrogen) with 5 mmol/l sodium butyrate (1,200 ml) after 24 h. Four days later, the conditioned medium was harvested, filtered, and stored at 4degreesC. CNTO736 was purified using a Protein A MabSelect column (GE Healthcare) and Immunopure Gentle Ag/Ab binding and elution buffers (Pierce). The purified product was dialyzed into 20 mmol/l Tris, pH 7.4. The final column was a Superdex 200 column (GE Healthcare) in PBS. Selected fractions were pooled and concentrated.
###end p 16
###begin title 17
Cells and islets.
###end title 17
###begin p 18
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 52 57 <span type="species:ncbi:9606">Human</span>
###xml 62 80 <span type="species:ncbi:10116">Sprague-Dawley rat</span>
INS-1E cells were kindly provided by C.B. Wollheim. Human and Sprague-Dawley rat islets were isolated using an enzymatic digestion and density gradient purification as described (29).
###end p 18
###begin title 19
cAMP.
###end title 19
###begin p 20
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 127 128 127 128 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 292 293 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 107 113 <span type="species:ncbi:9913">bovine</span>
INS-1E cells were plated in 96-well plates (1 x 105 cells/well) in RPMI-1640 (Invitrogen) containing fetal bovine serum (10%), l-glutamine (1%), sodium pyruvate (1%), nonessential amino acids (1%), and beta-mercaptoethanol (50 mumol/l). The cells recovered for 4 days at 37degreesC with 5% CO2. Media was aspirated from the wells, and 24 mul of Alexa Fluor 647 anti-cAMP antibody (LANCE cAMP Kit; Perkin Elmer) was added followed by 24 mul of CNTO736 or a construct lacking a linker (in PBS/0.5% BSA/0.5 mmol/l isobutylmethylxanthine). The cells were stimulated at room temperature for 7 min and lysed per the manufacture's protocol (Perkin Elmer). The plates were incubated at room temperature for 1 h, and the fluorescence intensity was measured at 665 nm. cAMP concentrations were determined using a standard curve.
###end p 20
###begin title 21
###xml 23 26 <span type="species:ncbi:10116">rat</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Insulin secretion from rat or human islets.
###end title 21
###begin p 22
###xml 117 118 117 118 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 294 295 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 359 360 353 354 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 553 556 <span type="species:ncbi:10116">Rat</span>
###xml 667 672 <span type="species:ncbi:9606">human</span>
Islets were suspended at a density of 20 islets/ml in functionality/viability media (MediaTech) containing BSA (1%), l-glutamine (1%), penicillin/streptomycin (1%), and glucose (0.5 mmol/l). Approximately 20 islets were added to each well of a 24-well plate and incubated at 37degreesC in 5% CO2. After 2 h, functionality/viability media containing BSA (1%), l-glutamine (1%), penicillin/streptomycin (1%), CNTO736 (50 nmol/l), and glucose (3.5 or 15 mmol/l) was added. Supernatant was collected at baseline and after 4 h and was stored at -20degreesC. Rat insulin was quantitated using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) (Crystal Chem), and human insulin was quantitated by ELISA (Linco Research).
###end p 22
###begin title 23
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Pharmacokinetics of CNTO736 in mice.
###end title 23
###begin p 24
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:9925">goat</span>
###xml 550 555 <span type="species:ncbi:9606">human</span>
C57BL/6 mice were dosed intravenously with CNTO736 (1 mg/kg) or GLP-1 peptide (0.062 mg/kg; Sigma). At various times, three animals were killed and blood was collected via cardiac puncture in 3.8% sodium citrate containing protease inhibitors (Roche Complete EDTA free; Roche Applied Science). Plasma was isolated and stored at -80degreesC. The concentration of intact CNTO736 was measured using a modified form of a purchased ELISA designed to detect intact GLP-1 (Linco). Briefly, CNTO736 was captured as described in the protocol, but a goat anti-human H + L alk-phos conjugate (Jackson Immunoresearch) was used to detect intact CNTO736. Fluorescence was read and the data analyzed with Softmax-Pro (Molecular Devices).
###end p 24
###begin title 25
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Intraperitoneal insulin glucose test in DIO mice.
###end title 25
###begin p 26
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
Male DIO mice were randomized (n = 5) based on FBG. Mice were dosed intravenously with CNTO736, the negative control lacking the GLP-1 peptide, or PBS 10 min before an intraperitoneal glucose tolerance test (ipGTT).
###end p 26
###begin title 27
###xml 49 53 <span type="species:ncbi:10090">mice</span>
ipGTT and food intake in GLP-1 receptor knockout mice.
###end title 27
###begin p 28
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
Fasted male GLP-1 receptor knockout mice (n = 5) (30) and C57BL/6 age-matched controls (n = 6) were dosed intravenously with CNTO736 (1 mg/kg) or a negative control lacking the GLP-1 peptide. An ipGTT was done 30 min after dosing. In a separate study, fasted male GLP-1 receptor knockout mice (n = 5) and C57BL/6 age-matched controls (n = 6) were dosed subcutaneously with CNTO736 (1 mg/kg) or a negative control lacking the GLP-1 peptide, and food intake was measured over the next 24 h.
###end p 28
###begin title 29
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Gastric emptying in wild-type mice.
###end title 29
###begin p 30
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
Mice (n = 5) were fasted overnight (16-18 h), and fed preweighed food in the morning. After 1 h of refeeding, the remaining food was weighed for measurement of food intake, and mice were dosed intravenously with CNTO736 (2.4 mg/kg) or PBS (31). The animals were deprived of food for the remainder of the study. Four hours postdosing, the stomach was exposed by laparotomy, quickly ligated at both the pylorus and cardia, and removed. The wet weight of the stomach content was determined, and the amount of food retained in the stomach was calculated.
###end p 30
###begin title 31
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 60 64 <span type="species:ncbi:10116">rats</span>
Immunohistochemistry of anti-human IgG in brain sections of rats.
###end title 31
###begin p 32
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1045 1048 1038 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1089 1092 1082 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 0 19 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 212 216 <span type="species:ncbi:10116">rats</span>
###xml 369 372 <span type="species:ncbi:10116">rat</span>
###xml 1000 1005 <span type="species:ncbi:9606">human</span>
###xml 1187 1198 <span type="species:ncbi:3704">horseradish</span>
Sprague-Dawley rats (n = 3) were fasted for 24 h and dosed intravenously with PBS or CNTO736 (1 mg/kg) just before the dark cycle. After 30 min, 2 h, and 6 h, food and water intake measurements were recorded and rats were anesthetized with pentobarbital. Transcardial perfusion included PBS followed by paraformaldehyde (PFA) (4%) with sucrose. Following decapitation, rat skulls were stored overnight in PFA (4%) at 4degreesC. Brains were dissected, stored in PBS, and shipped to NeuroScience Associates (Knoxville, TN) for immunohistochemistry analysis. A multibrain block was prepared using MultiBrain Technology (NeuroScience Associates), frozen by immersion in chilled isopentane, and mounted on a freezing stage of an AO 860 sliding microtome. The MultiBrain block was sectioned coronally at 35 mu with sequential collection into a 4 x 5 array of containers filled with antigen preserve solution (50% PBS, pH 7.0; 50% ethylene glycol, 1% polyvinyl pyrrolidone). Sections were stained with anti-human Fc (Jackson ImmunoResearch) and anti-c-fos (Calbiochem) reagents for CNTO736 and c-fos, respectively. Antibody binding was visualized using appropriate secondary antibodies, avidin-horseradish peroxidase and diaminobenzidine tetrahydrochloride with hydrogen peroxide.
###end p 32
###begin title 33
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Chronic dosing in DIO mice.
###end title 33
###begin p 34
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
Male DIO mice (n = 7) were subcutaneously dosed daily with vehicle or CNTO736 (0.1 and 1 mg/kg) for 6 weeks. FBG was measured from tail vein blood using a hand-held glucometer (Lifescan) twice per week. Body weights were measured daily during the 6 weeks of dosing. Dual-energy X-ray absorptiometry analysis was done at the end of the 6-week study on the CNTO736 (1 mg/kg) and vehicle-treated groups.
###end p 34
###begin title 35
Statistical analysis.
###end title 35
###begin p 36
###xml 150 151 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 215 216 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
All values are presented as the means +/- SE. Comparisons among groups were made using ANOVA followed by unpaired, nonparametric two-tailed Student's t test. Differences were considered statistically significant at P < 0.05.
###end p 36
###begin title 37
RESULTS
###end title 37
###begin title 38
MIMETIBODY engineering.
###end title 38
###begin p 39
###xml 439 440 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 433 440 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 720 721 720 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 714 721 714 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 745 752 745 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 924 926 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
Various constructs were engineered to balance optimization of GLP-1 activity with maximal in vivo stability, concentrating the design on the linker because it is such a critical element. The linker must be flexible enough to enable effective engagement of the GLP-1 receptor yet stable enough to maintain in vivo attachment to the Fc portion of the molecule since it is responsible for imparting extended pharmacokinetic properties (Fig. 1A). To illustrate the importance of the linker, constructs with different linkers were evaluated. One variant in which the GLP-1 segment was linked directly to the Fc hinge had improved pharmacokinetic properties but was linked to significant decreases in receptor activity (Fig. 1B) and in vivo efficacy (Fig. 1C). The optimal variant, CNTO736, maintained the bioactivity of GLP-1, while extending the half life approximately1,000-fold compared with GLP-1 in mice (30 h vs. 1-2 min) (12).
###end p 39
###begin title 40
In vitro characterization.
###end title 40
###begin p 41
###xml 88 90 88 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 114 115 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 155 156 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 186 187 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 180 187 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 346 349 342 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 734 736 730 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 863 864 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 869 870 865 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 857 870 853 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 805 808 <span type="species:ncbi:10116">rat</span>
###xml 813 818 <span type="species:ncbi:9606">human</span>
CNTO736 increased cAMP accumulation in INS-1 cells in a dose-dependent manner with an EC50 of 4.9 +/- 2.5 nmol/l (n = 6) compared with 0.2 +/- 0.1 nmol/l (n = 5) for native GLP-1 (Fig. 1B shows one representative dataset). To directly compare the affinity of CNTO736 and GLP-1 binding to the GLP-1 receptor, competitive binding experiments using 125I-labeled GLP-1 demonstrated that binding of CNTO736 to GLP-1 receptor on INS-1 cells was approximately eightfold weaker than native GLP-1 (data not shown). Both the cAMP and binding studies indicate that addition of the hinge and Fc onto the GLP-1 peptide results in a decreased affinity for the receptor. Nevertheless, CNTO736 stimulated insulin secretion from INS-1 cells with an EC50 of 0.03 nmol/l (data not shown) and enhanced insulin secretion from rat and human islets in a glucose-dependent manner (Fig. 2A and B).
###end p 41
###begin title 42
###xml 13 17 <span type="species:ncbi:10090">mice</span>
ipGTT in DIO mice.
###end title 42
###begin p 43
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
The in vivo activity of CNTO736 was evaluated in an acute study to ascertain whether the molecule was able to reduce blood glucose levels. CNTO736 or a negative control lacking the GLP-1 peptide was dosed intravenously to DIO mice, and an ipGTT was performed 10 min later. CNTO736 reduced the glucose excursion in a dose-dependent manner (Fig. 3A). At 20 mug/kg CNTO736, the glucose area under the curve was reduced >35% relative to control animals, while the glucose area under the curve for mice treated with 100 mug/kg was reduced by 53%.
###end p 43
###begin title 44
###xml 47 51 <span type="species:ncbi:10090">mice</span>
ipGTT in wild-type and GLP-1 receptor knockout mice.
###end title 44
###begin p 45
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 327 334 327 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 424 427 424 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 440 441 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 434 441 434 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 593 596 589 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
To determine whether the glucoregulatory actions of CNTO736 were GLP-1 receptor dependent, we evaluated the activity of CNTO736 in GLP-1 receptor knockout (Glp1r-/-) mice (30). As previously demonstrated in DIO mice, wild-type mice dosed with CNTO736 (1 mg/kg) had significantly reduced circulating glucose following an ipGTT (Fig. 3B), while no change in blood glucose was observed following CNTO736 administration in Glp1r-/- mice (Fig. 3C). In addition, FBG was reduced significantly 30 min after administration of CNTO736 in wild-type mice (85 +/- 13 vs. 120 +/- 25 mg/dl) but not in Glp1r-/- mice (156 +/- 38 vs. 145 +/- 37 mg/dl).
###end p 45
###begin title 46
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Food intake in wild-type and GLP-1 receptor knockout mice and gastric emptying in wild-type mice.
###end title 46
###begin p 47
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 106 113 106 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 362 363 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 356 363 356 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
Treatment with CNTO736 (1 mg/kg) reduced 24-h food intake by 25% in wild-type, but not in Glp1r-/-, mice (Fig. 4A). In a separate study, gastric emptying was estimated by weighing stomach contents after mice were given a preweighed meal. There was a fivefold increase in retained stomach contents in animals dosed with CNTO736 relative to control animals (Fig. 4B).
###end p 47
###begin title 48
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 65 69 <span type="species:ncbi:10116">rats</span>
Fc and c-fos immunohistochemistry in brain sections of wild-type rats.
###end title 48
###begin p 49
###xml 420 423 420 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 792 793 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 794 795 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 786 795 786 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#8211;<italic>I</italic></xref>
###xml 809 812 809 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 962 963 962 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 964 965 964 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 956 965 956 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic>&#8211;<italic>I</italic></xref>
###xml 1041 1044 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 449 453 <span type="species:ncbi:10116">rats</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
Some actions of small peptidic GLP-1 receptor agonists have been attributed to activation of central receptors that regulate food intake and satiety. We anticipated that the molecular weight of CNTO736 would inhibit its passage across the blood-brain barrier and limit its ability to regulate food intake. To assess whether peripherially administered CNTO736 could access central GLP-1 receptors and directly activate c-fos expression in the brain, rats were dosed intravenously with CNTO736 and brains were isolated 2 or 6 h after dosing. Brains were sectioned and stained for the presence of human Fc. CNTO736 was detected in the median eminence and area postrema of the nucleus of the solitary tract at both the 2- and 6-h time points but not in the central nucleus of the amygdale (Fig. 5A-I). However, c-fos expression could be detected via immunohistochemistry in the central nucleus of the amygdale as well as in the hypothalamus and area postrema (Fig. 6A-I). The appearance of CNTO736 in the median eminence and area postrema and c-fos expression in the hypothalamus, area postrema, and amygdale correlated with reductions in food and water intake (data not shown).
###end p 49
###begin title 50
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Chronic dosing in DIO mice.
###end title 50
###begin p 51
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 88 95 88 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>A</italic></xref>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 274 281 274 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>B</italic></xref>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 444 451 444 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7<italic>C</italic></xref>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
DIO mice dosed chronically with CNTO736 demonstrated a dose-dependent reduction in FBG (Fig. 7A). In addition, treatment with CNTO736 over a 6-week period reduced body weight by 7.8 or 19.8% relative to control mice after 6 weeks for the 0.1 or 1 mg/kg doses, respectively (Fig. 7B). Dual-energy X-ray absorptiometry analysis indicated that the reduction in body weight was primarily due to a loss of fat mass, while muscle mass was unchanged (Fig. 7C).
###end p 51
###begin title 52
DISCUSSION
###end title 52
###begin p 53
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 1291 1292 1291 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1285 1292 1285 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1314 1316 1314 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1317 1319 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
Protein therapeutics represent the fastest-growing segment in the pharmaceutical industry. The increasing success rate of antibody therapeutics has fueled an interest in expanding the utility of protein therapeutics to address other unmet medical needs (32). Peptides represent a rich source of therapeutic targets, but unmodified peptides have not traditionally made good drugs because of their high rates of metabolism and clearance. A technology that could couple the desirable pharmacological properties of antibodies with the bioactivity of small peptides would be a valuable extension of antibody technology. The MIMETIBODY platform was developed to address the gap between large protein and small peptide molecules. A variety of peptides were engineered into the platform to demonstrate the utility and versatility of the platform. This novel class of proteins provides a scaffold for display and delivery of bioactive peptides that is unique from other fusion protein technologies. The placement of the genetic fusion and the nature of the linker sequence are critical for maintenance of peptide activity. During engineering of CNTO736, we have tested a construct in which the GLP-1 moiety was fused directly to the hinge of the Fc; this construct exhibited very low activity (Fig. 1B). Similarly, others (31,33) have reported that fusion of a GLP-1 analogue to an IgG1 Fc or albumin results in nearly 100-fold lower activity. Thus, optimization of the linker sequence is an essential component of the MIMETIBODY technology.
###end p 53
###begin p 54
###xml 312 313 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 314 316 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 317 319 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 371 372 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 403 405 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 406 408 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 433 435 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 436 438 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 482 484 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 485 487 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 488 490 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 491 493 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 599 600 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 600 603 591 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1/2</sub>
###xml 629 631 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 632 634 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
We have used our novel MIMETIBODY platform to engineer a molecule with potential for application to type 2 diabetes. GLP-1 receptor agonists have gained significant attention because of several attractive properties of the peptide. GLP-1 stimulates insulin release from beta-cells in a glucose-dependent manner (7,10,34), increases insulin biosynthesis in the beta-cell (7), regulates gastric emptying (13-15), inhibits food intake (35-37), and increases beta-cell mass in rodents (16,17,19-21). However, GLP-1 itself is not a desirable therapeutic because of its extremely short in vivo half-life (T1/2 = approximately1-2 min) (11,12). Our data demonstrate that CNTO736 maintains the bioactivity properties of the native hormone while significantly enhancing the half-life.
###end p 54
###begin p 55
CNTO736 is a macromolecule containing two GLP-1 moieties, and our data demonstrate that its activity is similar to native GLP-1. CNTO736 binds to the GLP-1 receptor, induces cAMP production, and increases insulin secretion in a glucose-dependent manner. CNTO736 also reduces fasting and postprandial blood glucose and reduces A1C after chronic dosing.
###end p 55
###begin p 56
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1191 1196 1191 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 1233 1234 1229 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
###xml 1135 1139 <span type="species:ncbi:10090">mice</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
One potential concern for any long-lived GLP-1 receptor agonist is that continual exposure to the peptide could result in receptor tachyphylaxis. However, continuous infusion of native GLP-1 in type 2 diabetic patients reduced blood glucose equally after 1 or 6 weeks of treatment, indicating that the receptor was present and accessible throughout treatment (23). A second study comparing a 16- vs. 24-h GLP-1 infusion in patients indicated that greater efficacy could be achieved with sustained 24-h coverage (38), with no evidence of tachyphylaxis or loss of activity. Finally, treatment with exendin-LAR has been reported to reduce A1C as much as 2% in the high-dose group (39). Since the half-life for exendin-LAR was reported to be 14-15 days, the data confirms that sustained exposure to a GLP-1 analogue has potential for profound efficacy. Diabetic mice dosed chronically with CNTO736 achieved a significant reduction in FBG, and an oral glucose tolerance test performed at the end of the study showed no evidence of tachyphylaxis. Consistent with a prolonged reduction in blood glucose levels, A1C was significantly lower in mice treated with CNTO736 compared with vehicle-treated db/db mice (7.2 +/- 1.1 vs. 8.4 +/- 1.1%, P < 0.05) (data not shown).
###end p 56
###begin p 57
###xml 111 116 <span type="species:ncbi:9606">human</span>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 420 425 <span type="species:ncbi:9606">human</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
A second issue relates to the potential for an immune response in animals treated with CNTO736 that contains a human Fc. We anticipated that an immune response could attenuate the activity of CNTO736 in mouse models. Thus, although CNTO736 showed prolonged pharmacokinetics following a single dose in mice, animals were dosed daily to ensure continuous coverage in chronic experiments. Despite the likelihood of an anti-human Fc response, efficacy was maintained in mice dosed chronically with CNTO736.
###end p 57
###begin p 58
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 698 701 698 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 905 908 905 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1104 1106 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
A significant component of the observed efficacy in patients treated with byetta or liraglutide arises from a reduction in food intake and body weight (24,40-42). Our data demonstrate that peripheral dosing of CNTO736 decreases food intake and chronic dosing reduces body weight. It remains unclear whether peripherally or centrally located receptors mediate the GLP-1 effect on food intake, and we anticipated that the molecular weight of CNTO736 would preclude its passage across the blood-brain barrier. Immunohistochemistry was used to test the hypothesis directly, and CNTO736 was detected only in brain regions that are readily available to circulation (circumventricular organs). However, c-fos activation was observed in the amygdale. Therefore, GLP-1 receptors that influence food intake are likely located either in the periphery or in an area of the brain that is exposed to circulation. Our c-fos activation data are consistent with previous reports that neurons found in the area postrema are important for transmitting signals from the periphery to the central autonomic regulatory system (43).
###end p 58
###begin p 59
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 941 944 941 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1108 1111 1108 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 1387 1390 1387 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 1792 1793 1792 1793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1793 1796 1793 1796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 1959 1960 1959 1960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1960 1963 1960 1963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max</sub>
###xml 349 352 <span type="species:ncbi:10116">rat</span>
A major adverse event associated with the incretin mimetics is nausea. Although the mechanism for nausea is not well understood, it has been speculated that a delay in gastric emptying may play a role. Alternatively, it is likely that there is a central component to the nausea. Experiments in which GLP-1 was dosed directly into various regions of rat brains followed by a conditioned taste aversion test suggest that receptors located in the central nucleus of the amygdala mediate visceral illness (44). A significant difference between CNTO736 and many GLP-1 receptor agonists evaluated in the clinic thus far is its size. Byetta and liraglutide are low-molecular weight peptides that are likely to cross the blood-brain barrier. Since the central nucleus of the amygdala is an area of the brain that is protected by the blood-brain barrier, CNTO736 is unable to directly activate receptors there following peripheral dosing. However, c-fos is activated in the amygdale following peripheral dosing of CNTO736. Peripheral dosing of albugon, another large molecule GLP-1 receptor agonist, also activated c-fos in many areas of the brain that are not likely to be accessible to large molecules, including the central nucleus of the amygdala (31). Thus, it is likely that there is a peripheral mechanism that allows for activation of receptors in central nervous system centers. Since c-fos signaling from albugon was less robust than that of exenatide, it is possible that central and peripheral mechanisms act in concert to mediate the complete pharmacology of GLP-1. It may be possible to separate the negative (i.e., nausea) events associated with GLP-1 therapeutics by minimizing localization in the central nervous system. Regardless of the predominant mechanism, a correlation between Cmax and nausea has been observed for GLP-1 receptor peptide agonists. A molecule with an extended and flattened pharmacokinetic profile may be expected to have fewer Cmax-related side effects. Taken together, we anticipate that the MIMETIBODY platform may enable the desired activities of GLP-1 with minimal adverse events.
###end p 59
###begin p 60
In conclusion, the data presented suggest that our novel MIMETIBODY platform can be used to improve the properties of a bioactive peptide, rendering it more suitable for therapeutic use. CNTO736 is a potent GLP-1 analogue with potential to improve treatment of type 2 diabetes. The half-life of CNTO736 is substantially longer than native GLP-1, byetta, or liraglutide. It is tempting to speculate that sustaining superphysiological levels of a GLP-1 receptor agonist will translate into significant improvements in efficacy with less frequent dosing and the potential to inhibit disease progression. These data illustrate the potential for applying the MIMETIBODY platform to enhance the properties of agonist peptide therapeutics for metabolic diseases. More generally, identification of agonist antibodies or small molecule drugs for multitransmembrane receptors remains challenging, and the MIMETIBODY platform provides a technology to address this gap and enable peptide agonist drug development.
###end p 60
###begin p 61
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 158 161 <span type="species:ncbi:10116">rat</span>
We thank the Diabetes Research Institute at the University of Miami for kindly providing human islets. In addition, we thank Cindy Duchala for preparation of rat islets. We thank Sreedevi Adhikarakunnathu, Heather Deutsch, Stacy Hudgins, Dorie Makropoulos, Christine McCauley, and Justin Sprenkle for expert technical assistance. We thank Eva Emmell, Michael Lark, Simon Blake, Peter Bugelski, and John O'Neil for critical advice and guidance.
###end p 61
###begin title 62
REFERENCES
###end title 62
###begin p 63
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 327 328 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 617 619 609 611 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 635 636 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 656 657 648 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 881 882 839 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
CNTO736 has improved activity relative to constructs lacking a linker. A: The schematic outlines the structure of CNTO736 including the CH2 and CH3 domains of the Fc, the hinge including the disulfide bonds, a linker containing a partial VH region, and two GLP-1 peptides. The amino acid sequence of CNTO736 beginning at the NH2-terminus is as follows: HSEGTFTSDVSSYLEGQAAKEFIAWLVKGRGGGSGGGSGTLVTVSSESKYGPPCPPCPAPEAAem leader Fc B. The concentration of cAMP was measured in INS-1E cells after addition of increasing concentrations of CNTO736 or a molecule lacking the hinge. The fit to the CNTO736 data provided an EC50 of 1.8 nmol/l. C: Fasted mice (DIO, n = 5) were dosed intravenously with vehicle (blacksquare, square, filled), CNTO736 (0.5 mg/kg) (diamond), or a construct lacking a hinge (0.5 mg/kg) (o) 10 min before an ipGTT. The results are presented as the means +/- SE (n = 5).
###end p 63
###begin p 64
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 53 56 <span type="species:ncbi:10116">Rat</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
CNTO736 induces glucose-dependent insulin secretion. Rat islets (A) or human islets (B) were incubated with CNTO736 (50 nmol/l) in the presence of low or high glucose, and the concentration of secreted insulin was measured after 4 h.
###end p 64
###begin p 65
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 295 296 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 320 321 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 446 447 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 487 488 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 647 648 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
CNTO736 improves glucose tolerance in normal and DIO mice but not GLP-1 receptor knockout mice. A: Fasted mice (DIO, n = 5) were dosed intravenously with CNTO736 [0.02 (blacksquare, square, filled) and 0.1 (*) mg/kg] or the negative control lacking the GLP-1 peptide (o) 10 min before an ipGTT. B: Fasted mice (C57BL/6, n = 6) were dosed intravenously with CNTO736 (1 mg/kg) (square) or the negative control (1 mg/kg) (*) 30 min before an ipGTT. C: Fasted mice (GLP-1 receptor knockout, n = 5) were dosed intravenously with CNTO736 (1 mg/kg) (square) or control (1 mg/kg) (*) 30 min before an ipGTT. The results are presented as the means +/- SE (n = 5).
###end p 65
###begin p 66
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 148 149 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 330 331 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 339 340 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 354 355 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 370 371 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 749 750 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 759 760 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
CNTO736 decreases food intake and delays gastric emptying. A: Fasted GLP-1 receptor knockout (n = 5) (blacksquare, square, filled) or C57BL/6 mice (n = 6) (square) were dosed subcutaneously with CNTO736 (1 mg/kg) or a negative control (1 mg/kg). Food intake was monitored over 24 h. The results are presented as the means +/- SE (n = 5). *P value <0.05. B: Fasted mice (n = 5) were given a preweighed meal and the amount of food consumed in 1 h was measured. The mice were dosed intravenously with CNTO736 (2.4 mg/kg) or vehicle and were killed after 4 h. The wet weight of the stomach contents was measured to determine what percent of the food remained in the stomach as an estimate of gastric emptying. The results are presented as means +/- SE (n = 10). *P value <0.05.
###end p 66
###begin p 67
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 199 200 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 227 228 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 683 684 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 685 686 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 693 694 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 707 708 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 709 710 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 153 157 <span type="species:ncbi:10116">rats</span>
###xml 521 526 <span type="species:ncbi:9606">human</span>
###xml 634 638 <span type="species:ncbi:10116">rats</span>
CNTO736 is present in the area of the hypothalamus and circumventricular organs but not in the amygdale following peripheral dosing. Brain sections from rats (n = 3) dosed intravenously with PBS (A, D, and G), CNTO736 for 2 h (B, E, and H) and CNTO736 for 6 h (C, F, and I). Brain sections were taken at the level of the median eminence (ME) (A-C), central nucleus of the amygdale (AMYG) (D-F), and area postrema (AP), including nucleus of the solitary tract (NTS) (G-I). Coronal brain sections were stained with an anti-human IgG antibody to detect the presence of CNTO736. The images are representative of sections taken from three rats per group. Picture magnification was 4x for A-C and G-I and 10x for D-F. Staining in PBS treated animals at 2 and 6 h postinjection were identical. Additional abbreviations include central canal (CC), third ventricle (3v), and arcuate nucleus (Arc).
###end p 67
###begin p 68
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 274 275 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 345 346 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 590 593 590 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fos</italic>
###xml 155 159 <span type="species:ncbi:10116">rats</span>
###xml 523 527 <span type="species:ncbi:10116">rats</span>
Peripheral treatment of CNTO736 leads to neuronal activation of several brain areas as measured by c-fos immunohistochemical staining. Brain sections from rats (n = 3) dosed intravenously with PBS (A, D, and G), CNTO736 for 2 h (B, E, and H), and CNTO736 for 6 h (C, F, and I). Brain sections were taken at the level of the hypothalamus (HYPO) (A-C), central nucleus of the amygdale (AMYG) (D-F), area postrema (AP), and nucleus of the solitary tract (NTS) (G-I). The images are representative of sections taken from three rats per group. Coronal brain sections were stained with an anti-c-fos antibody. All pictures were taken at a x10 magnification. Staining of PBS-treated animals at 2 and 6 h postinjection were identical. PVH, paraventricular nucleus of the hypothalamus.
###end p 68
###begin p 69
###xml 206 207 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 214 215 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 240 241 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 256 257 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 439 440 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 448 449 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Chronic CNTO736 dosing improves glucose control and decreases body weight in DIO mice. CNTO736 (0.1 mg/kg) (square) and (1 mg/kg) (black triangle) or vehicle (*) was dosed subcutaneously daily for 6 weeks (n = 7). A: Fasting blood glucose. B: Body weight. C: Dual-energy X-ray analysis for lean and fat mass in the vehicle (blacksquare, square, filled) and CNTO736 groups (1 mg/kg) (square). The results are presented as the means +/- SE (n = 5). *P value <0.05.
###end p 69

